Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy

The New England Journal of Medicine
Jerry R MendellBrian K Kaspar

Abstract

Spinal muscular atrophy type 1 (SMA1) is a progressive, monogenic motor neuron disease with an onset during infancy that results in failure to achieve motor milestones and in death or the need for mechanical ventilation by 2 years of age. We studied functional replacement of the mutated gene encoding survival motor neuron 1 (SMN1) in this disease. Fifteen patients with SMA1 received a single dose of intravenous adeno-associated virus serotype 9 carrying SMN complementary DNA encoding the missing SMN protein. Three of the patients received a low dose (6.7×1013 vg per kilogram of body weight), and 12 received a high dose (2.0×1014 vg per kilogram). The primary outcome was safety. The secondary outcome was the time until death or the need for permanent ventilatory assistance. In exploratory analyses, we compared scores on the CHOP INTEND (Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders) scale of motor function (ranging from 0 to 64, with higher scores indicating better function) in the two cohorts and motor milestones in the high-dose cohort with scores in studies of the natural history of the disease (historical cohorts). As of the data cutoff on August 7, 2017, all 15 patients were alive and event-free...Continue Reading

References

Feb 13, 2002·Genetics in Medicine : Official Journal of the American College of Medical Genetics·Matthew D MailmanThomas W Prior
Apr 9, 2004·Food and Nutrition Bulletin·Trudy M WijnhovenBadriya al Rashidi
Sep 1, 2007·Journal of Child Neurology·Ching H WangUNKNOWN Participants of the International Conference on SMA Standard of Care
Jul 30, 2008·Journal of Medical Genetics·S Rudnik-SchönebornK Zerres
Dec 23, 2008·Nature Biotechnology·Kevin D FoustBrian K Kaspar
Sep 1, 2009·American Journal of Human Genetics·Thomas W PriorJohn T Kissel
Jun 12, 2010·Science Translational Medicine·Chiara F ValoriMimoun Azzouz
Dec 2, 2010·Human Molecular Genetics·Elisa DominguezMartine Barkats
Mar 4, 2011·Science Translational Medicine·Marco A PassiniSeng H Cheng
Aug 4, 2011·European Journal of Human Genetics : EJHG·Elaine A SugarmanBernice A Allitto
Nov 18, 2011·Pediatric Physical Therapy : the Official Publication of the Section on Pediatrics of the American Physical Therapy Association·Allan M GlanzmanUNKNOWN Muscle Study Group (MSG)
Aug 29, 2012·Annals of Neurology·Melissa BowermanRashmi Kothary
Dec 12, 2012·Trends in Molecular Medicine·Gillian Hamilton, Thomas H Gillingwater
Jan 23, 2016·Human Gene Therapy·Elizabeth A HarringtonCharles Paul Venditti
Oct 30, 2016·Neuromuscular Disorders : NMD·Roberto De SanctisEugenio Mercuri

❮ Previous
Next ❯

Citations

Feb 1, 2018·The New England Journal of Medicine
Feb 10, 2018·Nature Reviews. Neurology·Ewout J N GroenThomas H Gillingwater
Jan 20, 2018·Nature Reviews. Neurology·Enrico Bertini, Eugenio Mercuri
Mar 30, 2018·Human Gene Therapy Methods·Dan WangGuangping Gao
Dec 15, 2017·Nucleic Acids Research·Xiulong Shen, David R Corey
Apr 4, 2018·Current Rheumatology Reports·Kyla A BritsonThomas E Lloyd
Mar 27, 2018·The Journal of Gene Medicine·Samantha L GinnMohammad R Abedi
May 17, 2018·Der Nervenarzt·M RegensburgerZ Kohl
May 24, 2018·Pediatric Pulmonology·William A GowerTerry L Noah
Dec 16, 2017·Human Gene Therapy. Clinical Development·Alex Philippidis
Dec 16, 2017·Human Gene Therapy. Clinical Development·James M Wilson
May 22, 2018·Expert Opinion on Biological Therapy·Sara AgutiHaiyan Zhou
Jun 6, 2018·Macromolecular Rapid Communications·Zheng LuoYun-Long Wu
Jun 26, 2018·Expert Opinion on Biological Therapy·Anthony Donsante, Nicholas M Boulis
Jun 19, 2018·Brain : a Journal of Neurology·Emily R BurnsideElizabeth J Bradbury
Aug 7, 2018·Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies·Jonathan C Gilleland, Christopher S Parshuram
Aug 11, 2018·Nature Reviews. Drug Discovery·Benjamin E DevermanDinah W Y Sah
Aug 2, 2018·Expert Opinion on Biological Therapy·Joost van HaasterenDeborah R Gill
Aug 17, 2018·Journal of Child Neurology·Eliza Gordon-Lipkin, Ali Fatemi
Mar 20, 2018·Journal of Neurology, Neurosurgery, and Psychiatry·Michelle A FarrarMonique M Ryan
Aug 21, 2018·Expert Opinion on Drug Discovery·Ewout J N Groen
Jul 22, 2018·Current Opinion in Neurology·Cindy V Ly, Timothy M Miller
Sep 18, 2018·Developmental Medicine and Child Neurology·Teresa Gidaro, Laurent Servais
Sep 25, 2018·Journal of Neurogenetics·Jeffrey D Calhoun, Gemma L Carvill
Aug 3, 2018·Human Gene Therapy·Silveli Suzuki-HatanoChristina A Pacak
Oct 4, 2018·Human Gene Therapy·Thierry VandenDriessche
Oct 24, 2018·The Journal of Clinical Investigation·Klaudia KurandaFederico Mingozzi
Jan 11, 2019·Human Gene Therapy·Terence R Flotte
Dec 18, 2018·Transcription·Emma R HinkleJimena Giudice
Nov 28, 2018·Human Molecular Genetics·Kimberly K LongAdriana Donovan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell-Type Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type-Specific Viral Vectors (ASM)

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

AAV-based Gene Therapy

Adeno-associated virus (AAV)-based gene therapy is a biological vector that is being researched to be used as a potential therapeutic option. This gene therapy is designed to insert fragments of DNA into targeted cells to help treat diseases, such as hemophilia a. Discover the latest research on AAV-based gene therapy here.

Cell-Type-Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cajal Bodies & Gems

Cajal bodies or coiled bodies are dense foci of coilin protein. Gemini of Cajal bodies, or gems, are microscopically similar to Cajal bodies. It is believed that Cajal bodies play important roles in RNA processing while gems assist the Cajal bodies. Find the latest research on Cajal bodies and gems here.

Related Papers

Pediatric Physical Therapy : the Official Publication of the Section on Pediatrics of the American Physical Therapy Association
A M GlanzmanMuscle Study Group (MSG)
The New England Journal of Medicine
Amit C NathwaniAndrew M Davidoff
Pediatric Physical Therapy : the Official Publication of the Section on Pediatrics of the American Physical Therapy Association
Donna Cech, Nancy L Biedry
Zhonghua er ke za zhi. Chinese journal of pediatrics
Juan DUFang Song
© 2022 Meta ULC. All rights reserved